Pono Capital Corp Confirms Funding to Extend Period to Consummate Initial Business Combination
Honolulu, Hawaii, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pono Capital Corp (the “Company”) (Nasdaq: PONO), a special purpose acquisition company, today...
Pono Capital Corp Announces Termination of Merger Agreement with Benuvia, Inc.
Honolulu, Hawaii, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pono Capital Corp (NASDAQ: PONO) (the “Company” or “Pono”), a special purpose acquisition company,...
Benuvia, a Leading Drug Developer Focused on Pharmaceutical Cannabinoids, with the FDA Approved Drug SYNDROS®, Signs Definitive Agreement to Become a Publicly Traded Company through a Business Combination with Pono Capital Corp
Benuvia, a leading drug developer focused on pharmaceutical cannabinoids has entered into a definitive business combination agreement with Pono Capital...
Pono Capital Corp Announces Closing of Underwriters’ Option to Purchase Additional Units in Connection with its Initial Public Offering
HONOLULU, HI / ACCESSWIRE / August 18, 2021 / Pono Capital Corp (the "Company") today announced that it closed the issuance of an additional 1,500,000 units pursuant to the exercise of the underwriters'...